Reported Earnings • May 11
First quarter 2026 earnings released: EPS: US$0.004 (vs US$0.001 loss in 1Q 2025) First quarter 2026 results: EPS: US$0.004 (up from US$0.001 loss in 1Q 2025). Revenue: US$7.85m (up 11% from 1Q 2025). Net income: US$324.6k (up US$402.9k from 1Q 2025). Profit margin: 4.1% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Apr 22
Now 27% undervalued Over the last 90 days, the stock has risen 17% to CA$0.34. The fair value is estimated to be CA$0.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making. Announcement • Apr 14
Nova Leap Health Corp., Annual General Meeting, Jun 10, 2026 Nova Leap Health Corp., Annual General Meeting, Jun 10, 2026. Reported Earnings • Mar 08
Full year 2025 earnings released: US$0.002 loss per share (vs US$0.016 profit in FY 2024) Full year 2025 results: US$0.002 loss per share (down from US$0.016 profit in FY 2024). Revenue: US$31.5m (up 22% from FY 2024). Net loss: US$189.9k (down 114% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Jan 02
Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States, Effective January 1, 2026 Nova Leap Health Corp. has promoted Melissa Anderson from her role as Vice President, Operations (U.S.) to Senior Vice President (U.S.), effective January 1, 2026. Melissa Anderson joined Nova Leap in 2018 and has played a central role in advancing the Company’s U.S. operations through disciplined execution, operational improvements, strengthened regional leadership structures, and EBITDA growth across the division. In her expanded role, Melissa will oversee Nova Leap’s U.S. home care operations, including strategic planning, operational performance, expansion into new states, and integration of new service lines, including the Company’s recently launched Care Management division. Reported Earnings • Nov 09
Third quarter 2025 earnings released: EPS: US$0.005 (vs US$0.002 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.005 (up from US$0.002 loss in 3Q 2024). Revenue: US$8.26m (up 29% from 3Q 2024). Net income: US$426.2k (up US$634.0k from 3Q 2024). Profit margin: 5.2% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Oct 06
Now 25% undervalued Over the last 90 days, the stock has risen 5.4% to CA$0.29. The fair value is estimated to be CA$0.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 66%. Buy Or Sell Opportunity • Sep 12
Now 27% undervalued Over the last 90 days, the stock has risen 5.6% to CA$0.28. The fair value is estimated to be CA$0.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 66%. Buy Or Sell Opportunity • Aug 19
Now 21% undervalued Over the last 90 days, the stock has risen 15% to CA$0.31. The fair value is estimated to be CA$0.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 66%. Reported Earnings • Aug 10
Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.003 profit in 2Q 2024) Second quarter 2025 results: US$0.006 loss per share (down from US$0.003 profit in 2Q 2024). Revenue: US$8.02m (up 27% from 2Q 2024). Net loss: US$484.0k (down 313% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • May 09
First quarter 2025 earnings released: US$0.001 loss per share (vs US$0.005 profit in 1Q 2024) First quarter 2025 results: US$0.001 loss per share (down from US$0.005 profit in 1Q 2024). Revenue: US$7.09m (up 10% from 1Q 2024). Net loss: US$78.3k (down 117% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • May 05
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to CA$0.30. The fair value is estimated to be CA$0.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Mar 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$19.2m market cap, or US$13.4m). Reported Earnings • Mar 07
Full year 2024 earnings released: EPS: US$0.016 (vs US$0.012 loss in FY 2023) Full year 2024 results: EPS: US$0.016 (up from US$0.012 loss in FY 2023). Revenue: US$25.8m (down 1.6% from FY 2023). Net income: US$1.38m (up US$2.43m from FY 2023). Profit margin: 5.4% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 25% per year. Announcement • Jan 20
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Earth Angels Living Assistance Inc. and Earth Angels South Shore Inc. Nova Leap Health Corp. (TSXV:NLH) entered into an agreement to acquire Earth Angels Living Assistance Inc. and Earth Angels South Shore Inc. for CAD 1.38 million on October 29, 2024. Consideration consists of CAD 1.38 million, on a cash-free, debt-free basis and subject to customary post-closing working capital adjustments, with the full amount payable in cash on closing. The CAD 1.38 million purchase price will be funded by way of a debt facility with the Company’s lender and is repayable over a five year term. The Targets reported aggregate unaudited revenue of approximately CAD 2.56 million, unaudited net income of approximately CAD 0.235 million and Adjusted EBITDA1 of approximately CAD 0.276 million for the 2023 fiscal year. Completion of the Transaction is subject to the satisfaction of certain conditions, including the approval of the TSXV, Nova Leap Health Corp. shareholders and lender approval and has been approved by the Board, with unanimous support from all directors. The transaction is expected to close by the end of 2024. As of January 8, 2025, closing of the acquisition is expected to occur by the end of January.
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Earth Angels Living Assistance Inc. and Earth Angels South Shore Inc. on January 20, 2025. Announcement • Dec 17
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Assets of a home care services business with operations in Florida. Nova Leap Health Corp. (TSXV:NLH) entered into definitive agreement to Assets of a home care services business with operations in Florida for $1.6 million on October 11, 2024. A cash consideration of $1.32 million and promissory note of Nova Leap Health Corp. having a value of $0.32 million. The $1.32 million of cash on closing will be funded by way of a debt facility with the Company’s lender which is repayable over a five-year term. The transaction is subject to the satisfaction of certain conditions including the approval of the TSXV, shareholder approval, lender approval and state licensing. Closing of the acquisition is expected to occur in November. The acquisition is expected to be immediately accretive.
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Assets of a home care services business with operations in Florida on December 16, 2024. Reported Earnings • Nov 09
Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.004 profit in 3Q 2023) Third quarter 2024 results: US$0.002 loss per share (down from US$0.004 profit in 3Q 2023). Revenue: US$6.41m (down 2.2% from 3Q 2023). Net loss: US$207.9k (down 155% from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (CA$27.6m market cap, or US$20.1m). Reported Earnings • Aug 11
Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.002 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.003 (up from US$0.002 loss in 2Q 2023). Revenue: US$6.34m (down 5.1% from 2Q 2023). Net income: US$227.0k (up US$410.5k from 2Q 2023). Profit margin: 3.6% (up from net loss in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: US$0.005 (vs US$0.003 loss in 1Q 2023) First quarter 2024 results: EPS: US$0.005 (up from US$0.003 loss in 1Q 2023). Revenue: US$6.43m (flat on 1Q 2023). Net income: US$473.1k (up US$769.9k from 1Q 2023). Profit margin: 7.4% (up from net loss in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Anne Whelan was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 06
Nova Leap Health Corp., Annual General Meeting, Jun 07, 2024 Nova Leap Health Corp., Annual General Meeting, Jun 07, 2024. Reported Earnings • Mar 10
Full year 2023 earnings released Full year 2023 results: Revenue: US$26.2m (down 7.2% from FY 2022). Net loss: US$1.05m (loss widened 26% from FY 2022). Reported Earnings • Aug 11
Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0 in 2Q 2022) Second quarter 2023 results: US$0.002 loss per share (further deteriorated from US$0 in 2Q 2022). Revenue: US$6.68m (down 4.4% from 2Q 2022). Net loss: US$183.5k (loss widened US$158.8k from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Aug 11
Nova Leap Health Corp. Announces Impairment for the Second Quarter Ended June 30, 2023 Nova Leap Health Corp. announced impairment for the second quarter ended June 30, 2023. In second quarter 2023, a goodwill impairment of USD 350,567 was recorded in one of the company’s U.S. agencies. Announcement • Aug 04
Nova Leap Health Corp. to Report Q2, 2023 Results on Aug 10, 2023 Nova Leap Health Corp. announced that they will report Q2, 2023 results on Aug 10, 2023 New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (CA$15.1m market cap, or US$11.4m). Recent Insider Transactions • Jun 12
Independent Director recently bought CA$99k worth of stock On the 8th of June, Wayne Myles bought around 522k shares on-market at roughly CA$0.19 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$380k more in shares than they have sold in the last 12 months. Reported Earnings • May 13
First quarter 2023 earnings released: US$0.003 loss per share (vs US$0.005 loss in 1Q 2022) First quarter 2023 results: US$0.003 loss per share (improved from US$0.005 loss in 1Q 2022). Revenue: US$6.40m (down 12% from 1Q 2022). Net loss: US$296.9k (loss narrowed 24% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year. Reported Earnings • Mar 10
Full year 2022 earnings released: US$0.01 loss per share (vs US$0.024 profit in FY 2021) Full year 2022 results: US$0.01 loss per share (down from US$0.024 profit in FY 2021). Revenue: US$28.2m (up 33% from FY 2021). Net loss: US$835.7k (down 148% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: US$0.007 (vs US$0.016 in 3Q 2021) Third quarter 2022 results: EPS: US$0.007 (down from US$0.016 in 3Q 2021). Revenue: US$7.14m (up 36% from 3Q 2021). Net income: US$549.1k (down 56% from 3Q 2021). Profit margin: 7.7% (down from 24% in 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 12
Third quarter 2022 earnings released: EPS: US$0.007 (vs US$0.016 in 3Q 2021) Third quarter 2022 results: EPS: US$0.007 (down from US$0.016 in 3Q 2021). Revenue: US$7.14m (up 36% from 3Q 2021). Net income: US$549.1k (down 56% from 3Q 2021). Profit margin: 7.7% (down from 24% in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Healthcare industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Buying Opportunity • Oct 03
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CA$0.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • Sep 13
Now 27% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be CA$0.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company has become profitable. Announcement • Sep 09
Nova Leap Health Corp. announced that it has received CAD 2.385056 million in funding On September 8, 2022, Nova Leap Health Corp. closed the transaction. The company issued 6,814,445 common shares for gross proceeds of CAD 2,385,055.75 in the transaction. The common shares issued pursuant to the offering are subject to a hold period until January 9, 2023. The transaction included participation from insiders of the company subscribed for an aggregate of 5,600,087 common shares, owns 38.72% of the issued and outstanding common shares of the company. The company paid cash finder’s fees of CAD 12,000 which was equal to 6.0% of the gross proceeds of the Offering raised through certain brokers. Announcement • Aug 24
Nova Leap Health Corp. announced that it expects to receive CAD 2.5 million in funding Nova Leap Health Corp. announced a non-brokered private placement of up to 7,142,857 common shares at a price of CAD 0.35 per share for gross proceeds of up to CAD 2,499,999.95 on August 23, 2022. The transaction may include participation from insiders of the company who are expected to subscribe for up to CAD 1,960,000. The company may pay a cash finders' fee of up to 6% of the gross proceeds. Recent Insider Transactions • Aug 23
Independent Director recently bought CA$94k worth of stock On the 16th of August, Wayne Myles bought around 276k shares on-market at roughly CA$0.34 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$728k more in shares than they have sold in the last 12 months. Buying Opportunity • Aug 19
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be CA$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 12
Second quarter 2022 earnings released: EPS: US$0 (vs US$0.005 in 2Q 2021) Second quarter 2022 results: EPS: US$0 (down from US$0.005 in 2Q 2021). Revenue: US$6.99m (up 37% from 2Q 2021). Net loss: US$24.7k (down 107% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 50%, compared to a 18% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 13
First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.013 profit in 1Q 2021) First quarter 2022 results: US$0.005 loss per share (down from US$0.013 profit in 1Q 2021). Revenue: US$7.30m (up 45% from 1Q 2021). Net loss: US$389.7k (down 144% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 52%, compared to a 25% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 12
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: US$0.02 (up from US$0.019 in FY 2020). Revenue: US$21.3m (up 23% from FY 2020). Net income: US$1.76m (up 40% from FY 2020). Profit margin: 8.3% (up from 7.3% in FY 2020). Revenue missed analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 59%, compared to a 31% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Announcement • Feb 19
Nova Leap Health Corp., Annual General Meeting, Apr 21, 2022 Nova Leap Health Corp., Annual General Meeting, Apr 21, 2022. Recent Insider Transactions • Dec 23
Independent Director recently bought CA$99k worth of stock On the 20th of December, Wayne Myles bought around 165k shares on-market at roughly CA$0.60 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$605k more in shares than they have sold in the last 12 months. Announcement • Dec 14
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Home Care Business With Operations Located in Kentucky and Indiana. Nova Leap Health Corp. (TSXV:NLH) entered into a definitive agreement to acquire Home Care Business With Operations Located in Kentucky and Indiana for $4.75 million on November 11, 2021. Under the agreement, the acquisition is to be made for total consideration of $4.75 million of which $4.4 million is payable with cash on closing and $0.35 million is by way of a promissory note repayable over a two-year period. The target reported unaudited annualized 2021 year-to-date revenues of approximately $4.1 million and EBITDA of $825,000. The acquisition is expected to be immediately accretive, is at arm’s length and there are no finder fees to be paid. Closing of the acquisition is subject to state licensing.
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Home Care Business With Operations Located in Kentucky and Indiana on December 13, 2021. Recent Insider Transactions • Dec 03
Independent Chairman of the Board recently bought CA$53k worth of stock On the 30th of November, Dana Hatfield bought around 88k shares on-market at roughly CA$0.61 per share. This was the largest purchase by an insider in the last 3 months. This was Dana's only on-market trade for the last 12 months. Reported Earnings • Nov 06
Third quarter 2021 earnings released: EPS US$0.02 (vs US$0.007 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$5.26m (up 24% from 3Q 2020). Net income: US$1.26m (up 169% from 3Q 2020). Profit margin: 24% (up from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Announcement • Sep 21
Nova Leap Health Corp. (TSXV:NLH) acquired Business assets of a home care services company located in Oklahoma. Nova Leap Health Corp entered into an agreement to acquire Business assets of a home care services company located in Oklahoma for $1.1 million on August 3, 2021. The total consideration includes $0.8 million payable with cash on closing and $0.3 million by way of a promissory note repayable over a two-year period. Closing of the acquisition is subject to lender approval and state licensing. The acquisition is expected to be immediately accretive.
Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Business assets of a home care services company located in Oklahoma for $1.1 million on September 20, 2021. Reported Earnings • Aug 08
Second quarter 2021 earnings released: EPS US$0.01 (vs US$0.012 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$5.09m (up 28% from 2Q 2020). Net income: US$345.5k (up US$1.14m from 2Q 2020). Profit margin: 6.8% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions Derivative • Aug 07
Independent Director exercised options to buy CA$228k worth of stock. On the 3rd of August, Wayne Myles exercised options to buy 288k shares at a strike price of around CA$0.52, costing a total of CA$150k. This transaction amounted to 22% of their direct individual holding at the time of the trade. Since December 2020, Wayne's direct individual holding has increased from 1.16m shares to 1.28m. Company insiders have collectively bought CA$1.3m more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Jun 12
Nova Leap Health Corp. announced that it has received CAD 5.499999 million in funding On June 11, 2021, Nova Leap Health Corp. (TSXV:NLH) closed the transaction. The transaction included participation from Insiders of the company for 323,112 common shares. The company paid finder's fee in cash of CAD 129,009.59 which was equal to 6.0% of the gross proceeds of the Offering raised through certain brokers. Announcement • Jun 01
Nova Leap Health Corp. announced that it expects to receive CAD 1.999999 million in funding Nova Leap Health Corp. (TSXV:NLH) announced a non-brokered private placement of up to 2,777,777 common shares at a price of CAD 0.72 for gross proceeds of CAD 2,000,000 on May 21, 2020. The company will may pay a cash finders' fee of up to 6% of the gross proceeds. The transaction is expected to close on June 30, 2021. The securities issued will subject to a hold period of four months. The transaction is subject to the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. Reported Earnings • May 09
First quarter 2021 earnings released: EPS US$0.01 (vs US$0.005 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.02m (up 8.9% from 1Q 2020). Net income: US$882.2k (up 157% from 1Q 2020). Profit margin: 18% (up from 7.4% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Announcement • Mar 18
Nova Leap Health Corp. Appoints Marie Mullally to Board of Directors NOVA LEAP HEALTH CORP. announced that it has appointed Marie Mullally, President & CEO of CUA, to its Board of Directors effective March 16, 2021. The company also intends to nominate Anne Whelan, CEO of Seafair Capital, for election at Nova Leap’s April 29, 2021 Annual Meeting of Shareholders. Nova Leap’s Board regularly evaluates its composition to ensure it includes the appropriate skills, experience and perspective necessary to drive growth for Nova Leap shareholders. With the addition of these two new Director nominees, there will be six Board nominees for election at the Annual Meeting of Shareholders, five of whom are independent. Marie is the President and CEO of CUA, one of Atlantic Canada’s largest community banking institutions, a position she has held since 2011. She is also the current Chair of the Board of Nova Scotia Business Inc. Reported Earnings • Mar 14
Full year 2020 earnings released: EPS US$0.02 (vs US$0.017 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: US$17.3m (flat on FY 2019). Net income: US$1.26m (up US$2.31m from FY 2019). Profit margin: 7.3% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Analyst Estimate Surprise Post Earnings • Mar 14
Revenue misses expectations Revenue missed analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 39%, compared to a 71% growth forecast for the Healthcare industry in Canada. Announcement • Feb 27
Nova Leap Health Corp., Annual General Meeting, Apr 29, 2021 Nova Leap Health Corp., Annual General Meeting, Apr 29, 2021. Is New 90 Day High Low • Jan 05
New 90-day high: CA$0.87 The company is up 129% from its price of CA$0.38 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: CA$0.58 The company is up 66% from its price of CA$0.35 on 16 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 6.0% over the same period. Reported Earnings • Nov 08
Third quarter 2020 earnings released: EPS US$0.01 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.23m (down 4.4% from 3Q 2019). Net income: US$467.8k (up US$510.8k from 3Q 2019). Profit margin: 11% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Oct 27
New 90-day high: CA$0.48 The company is up 47% from its price of CA$0.33 on 28 July 2020. The Canadian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 20% over the same period. Is New 90 Day High Low • Oct 08
New 90-day high: CA$0.40 The company is up 16% from its price of CA$0.34 on 10 July 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 21% over the same period.